BPG is committed to discovery and dissemination of knowledge
Translational Research
Copyright: ©Author(s) 2026.
World J Clin Oncol. Nov 24, 2026; 17(11): 125917
Published online Nov 24, 2026. doi: 10.5306/wjco.125917
Figure 4
Figure 4 Immune-related transcriptional features, KEGG-GSEA patterns, and computationally predicted drug-response associations according to NFKB1 expression. A: Heatmaps of differential immune-related molecules between NFKB1-low and NFKB1-high tumors, including immunostimulators, chemokines, and immunoinhibitors; significance is indicated by superscript lowercase letters; B: Distribution comparisons of immune activation signatures between groups, including the T-cell–inflamed score, tertiary lymphoid structure signature, interferon-γ signature, and cytolytic activity, are shown as density plots with embedded box plots and P values; C: KEGG gene set enrichment analysis comparing the highest 30% and lowest 30% of TCGA-CRC samples ranked by NFKB1 expression. All genes were ranked according to the limma-derived log2 fold change. Positive normalized enrichment scores indicate relative enrichment in the NFKB1-high group, whereas negative scores indicate relative enrichment in the NFKB1-low group. Benjamini-Hochberg-adjusted P values were used to control the false discovery rate (FDR). Complete results are provided in Supplementary Table 7; D: Predicted drug sensitivity and mechanism-of-action mapping based on the pharmacogenomic resource Genomics of Drug Sensitivity in Cancer. Candidate compounds associated with subgroup-specific vulnerability are linked to their putative target pathways; edges represent drug–pathway associations. All available GDSC1 and GDSC2 compound–NFKB1 correlation coefficients and nominal P values from the original significant-result exports are provided in Supplementary Table 8. The source exports did not retain an FDR-adjusted P value column. These results are computational associations and do not represent observed clinical responses. aP < 0.05; bP < 0.01; cP < 0.001. TLS: Tertiary lymphoid structure; IFN-γ: Interferon-γ; CYT: Cytolytic.


Write to the Help Desk